The Latest Cardiac and Vascular News
The Federal court upheld a previous coronary stent win over Dr. David Jang Appeals court upholds Boston Scientific win over stent pioneer Jang BY BRAD PERRIELLO, MassDevice A federal appeals court today upheld a Boston Scientific (NYSE:BSX) win over coronary stent pioneer Dr. David […]
MARLBOROUGH, Mass., Sept. 25, 2017 /PRNewswire/ — Boston Scientific (NYSE: BSX) has launched the Resonate family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems featuring the HeartLogic Heart Failure Diagnostic to help physicians improve heart failure (HF) management. […]
DALLAS and MARLBOROUGH, Mass., Sept. 19, 2017 /PRNewswire/ — Boston Scientific (NYSE: BSX) today announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients (MultiSENSE) study evaluating the performance of the HeartLogic Heart Failure Diagnostic to predict impending heart failure (HF) decompensation. […]
PENANG, 11 April 2016 – Expanding its manufacturing footprint in the Asia Pacific region, Boston Scientific Corporation (NYSE: BSX) today marked the commencement of construction work on a regional manufacturing hub during a groundbreaking ceremony in Penang. Located at the Batu […]
FREMONT, Calif. and ST. LOUIS, Sept. 11, 2017 /PRNewswire/ — VENITI®, Inc., a leader in the advancement of treatment for deep venous disease, today announced that Boston Scientific will distribute the VICI VENOUS STENT under a limited global distribution agreement. The terms of the agreement […]
Valencia, CA – August 28, 2017 – SetPoint Medical, a clinical-stage biomedical technology company developing a bioelectronic therapy for chronic inflammatory diseases, announced today that it has secured $30 million in Series D equity financing. The Series D financing will provide […]
SAN DIEGO, Aug. 07, 2017 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) will hold a briefing call on Thursday, August 10, 2017 at 4:00 p.m. PDT (which is 9:00 a.m. AEST on Friday, 11 August 2017). […]
SAN DIEGO, Aug. 03, 2017 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) announces the expiration of Boston Scientific Corporation’s (“BSC”) exclusive right to negotiate for distribution of REVA’s coronary and peripheral bioresorbable scaffolds. BSC’s right to […]
Boston Scientific decides it’s too risky and that there are “bigger” problems to deal with. Boston Scientific to end Renuvia bioresorbable coronary stent program JULY 31, 2017 BY FINK DENSFORD, MassDevice Boston Scientific (NYSE:BSX) is looking to terminate its Renuvia bioresorbable coronary stent […]
Boston Scientific warns on fluke S-ICD death JULY 28, 2017 BY BRAD PERRIELLO , MassDevice Boston Scientific (NYSE:BSX) last month alerted physicians after learning of a fluke incident involving its S-ICD pacemaker, in which a patient died when the device’s memory was corrupted by […]
